Reuters: Health
Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Novartis wins FDA's breakthrough tag for lung cancer hopeful
Novartis wins FDA's breakthrough tag for lung cancer hopeful
Reuters: Health
Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Reuters: Health
Novartis has secured the U.S. Food and Drug Administration's Breakthrough Therapy Designation for its investigational medicine capmatinib, which it aims to file for approval later this year against a mutated form of lung cancer.
Subscribe to:
Post Comments (Atom)
Popular Posts
|
No comments:
Post a Comment